Prelude Therapeutics Incorporated
PRLD · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.21 | -0.04 | 0.07 | 0.19 |
| FCF Yield | -42.42% | -58.74% | -21.58% | -17.42% |
| EV / EBITDA | -1.16 | -0.58 | -2.26 | -3.56 |
| Quality | ||||
| ROIC | -33.29% | -27.88% | -22.17% | -19.34% |
| Gross Margin | 0.00% | 0.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.97 | 0.83 | 1.07 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | 2,189,659.57% | 1,912,831.18% | 1,912,831.18% | 1,912,831.18% |
| Free Cash Flow Growth | 23.87% | -64.82% | 23.98% | -16.84% |
| Safety | ||||
| Net Debt / EBITDA | 0.25 | 0.65 | -0.17 | -0.21 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,031.36 | -1,206.41 | 0.00 | 0.00 |